行情

LJPC

LJPC

Jolla制药
NASDAQ

实时行情|Nasdaq Last Sale

10.81
-0.52
-4.59%
盘后: 10.81 0 0.00% 16:26 09/18 EDT
开盘
11.30
昨收
11.33
最高
11.38
最低
10.74
成交量
22.93万
成交额
--
52周最高
22.67
52周最低
5.01
市值
2.93亿
市盈率(TTM)
-1.8195
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

LJPC 新闻

  • 沪指高开震荡 美联储宣布今年内第二次降息
  • 新浪财经.1小时前
  • 欧委会主席容克:无协议脱欧风险“非常真实”
  • 中国新闻网.3小时前
  • 巴西央行宣布降息50个基点 基准利率下调至5.5%
  • 第一财经.3小时前
  • 一文看懂美联储议息之夜:鲍威尔真的没胆识?今年还会降息吗
  • 澎湃新闻.4小时前

更多

所属板块

生物技术和医学研究
-0.65%
制药与医学研究
-0.05%

热门股票

名称
价格
涨跌幅

LJPC 简况

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
展开

Webull提供La Jolla Pharmaceutical Company的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。